Incyte Corp, encouraged by data from ruxolitinib for mylefibrosis, submitted a new drug application NDA to the FDA, requiring priority review.
http://finance.yahoo.com/news/Incyte-Submits-New-Drug-bw-2609692740.html?x=0&.v=1
This puts INCY and Novartis NVS substantially ahead of YMI Biosciences (YMI) if approval goes through in the right time frame.
http://finance.yahoo.com/news/Incyte-Submits-New-Drug-bw-2609692740.html?x=0&.v=1
This puts INCY and Novartis NVS substantially ahead of YMI Biosciences (YMI) if approval goes through in the right time frame.
